| Dr Richard Ballou Gallaher Jr, PHD | |
|
513 Thain Road, Lewiston, ID 83501-4140 | |
| (208) 743-0150 | |
| (208) 743-5358 |
| Full Name | Dr Richard Ballou Gallaher Jr |
|---|---|
| Gender | Male |
| Speciality | Psychologist |
| Location | 513 Thain Road, Lewiston, Idaho |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1376634345 | NPI | - | NPPES |
| 000010147148 | Other | ID | REGENCE BLUESHIELD |
| 041256289 | Medicaid | WA | |
| 550867358 | Other | ID | GENERAL INSURANCE NUMBER |
| Y0929 | Other | ID | IDAHO BLUE CROSS |
| 806984800 | Medicaid | ID |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 103T00000X | Psychologist | PSY-202154 (Idaho) | Primary |
| 103T00000X | Psychologist | PY00000815 (Washington) | Secondary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Richard Ballou Gallaher Jr, PHD 513 Thain Road, Lewiston, ID 83501-4140 Ph: (208) 743-0150 | Dr Richard Ballou Gallaher Jr, PHD 513 Thain Road, Lewiston, ID 83501-4140 Ph: (208) 743-0150 |
News Archive
New King's College London research suggests that people with a family history of bipolar disorder may 'age' more rapidly than those without a history of the disease.
The Multiple Myeloma Research Foundation (MMRF) today announced that its partner, Onyx Pharmaceuticals, Inc., received U.S. Food and Drug Administration (FDA) approval for Kyprolis (carfilzomib) for the treatment of patients with multiple myeloma who have received at least two prior therapies, including Velcade (bortezomib) for Injection and an immunomodulatory agent, such as Thalomid (thalidomide) or Revlimid (lenalidomide), and have demonstrated disease progression on or within 60 days of completion of the last therapy.
Healthpoint Biotherapeutics today announced that the results for its Phase 2b clinical trial investigating the efficacy of HP802-247 in venous leg ulcers is published on The Lancet, beginning August 3, 2012, with Online First access to the article, followed by print publication in the next issue.
Access Pharmaceuticals, Inc., today announced it has initiated a Phase I/II dose-escalating study of its proprietary, anti-cancer drug, Thiarabine, a nucleoside analog for patients with hematologic malignancies (cancers of the blood). The primary objective of the study is to determine the maximum tolerated dose (MTD) in two different dosing schedules with various leukemias and lymphomas and recommended Phase II dose. The program is being led by Hagop Kantarjian, M.D., Chair of the Department of Leukemia at The University of Texas MD Anderson Cancer Center in Houston, Texas.
A specialized pain management program for patients who underwent robotic surgery for urologic cancers resulted in just eight percent going home with narcotics after discharge, compared to 100 percent who would have received them without this enhanced recovery protocol.
› Verified 8 days ago
Dr. Kristy Anne Kuehfuss, PH.D. Psychologist Medicare: Accepting Medicare Assignments Practice Location: 1418 Grelle Ave, Lewiston, ID 83501 Phone: 208-631-5843 | |
Dr. Kevin Richard Kracke, PH.D. Psychologist Medicare: Accepting Medicare Assignments Practice Location: 422 17th St, Lewiston, ID 83501 Phone: 208-743-4680 Fax: 208-743-1756 | |
Rebecca J Alexander, PH.D Psychologist Medicare: Accepting Medicare Assignments Practice Location: 532 Bryden Ave, Lewiston, ID 83501 Phone: 208-798-5168 Fax: 208-798-5169 | |
Dr. Leanne Parker, PHD Psychologist Medicare: Not Enrolled in Medicare Practice Location: 1720 18th Ave, Lewiston, ID 83501 Phone: 208-746-4097 | |
Philip N Mackinnon, PH D Psychologist Medicare: Not Enrolled in Medicare Practice Location: 415 6th St, Lewiston, ID 83501 Phone: 208-743-2511 Fax: 208-799-5554 | |
Dr. Gary L. Grogan, PHD Psychologist Medicare: Not Enrolled in Medicare Practice Location: 633 Main Street, B#1, Lewiston, ID 83501 Phone: 208-724-0489 |